Actinium Pharmaceuticals
Develops targeted radiotherapies for cancer and transplant conditioning.
Something off on this page? Send us feedback.
Profile
Develops targeted radiotherapies and conditioning agents for cancer and transplant or cell/gene therapy, with clinical candidates and a preclinical solid-tumor program. The business remains development-stage: it has no approved products and depends on clinical progress, partners, isotope suppliers, and manufacturing.
Develops targeted cancer therapeutics and transplant-conditioning agents by linking antibodies to radioactive isotopes. The portfolio includes ATNM-400 for solid tumors, Actimab-A for AML/MDS and solid-tumor strategies, and the Iomab-ACT and Iomab-B conditioning programs.
Operates a single research, discovery, and clinical-development segment from New York, with all assets located in the United States. Work spans target selection, radioconjugate design, preclinical and clinical development, isotope and drug-product supply, and clinical-stage manufacturing build-out.
Has no approved products or product-sale revenue. Advancement depends on clinical and regulatory results, strategic partners for key programs, and specialized third parties for isotopes, manufacturing, storage, and distribution while its planned New York facility is not yet operational.
Company facts
Key statistics
Year to date −26.3% · Average volume (30d) 153.2K
Analysts
Ratings
Target range
Latest analyst notes
No analyst notes in the last 24 months.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026Q2 FY26 | $0.89 | $0.89 | 0.0% | $35.0M | $35.0M | 0.0% | +1.32% |
| May 8, 2026Q1 FY26 | −$0.22 | −$0.18 | +18.2% | $2.5M | — | — | +2.29% |
| Mar 30, 2026Q4 FY25 | −$0.19 | −$0.19 | −1.8% | $600.0K | — | — | +0.54% |
| Nov 14, 2025Q3 FY25 | −$0.25 | −$0.16 | +36.0% | $67.5K | $90.0K | +33.3% | +14.17% |
Financial highlights
| 11 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $90.0K | $0 | $0 | $35.0M | |
| Gross profit | $0 | $0 | $90.0K | $615.0K | −$220.0K | $35.0M | |
| Operating income | −$16.6M | −$7.5M | −$5.7M | −$6.4M | −$5.9M | $27.6M | |
| Net income | −$15.9M | −$6.9M | −$5.1M | −$5.9M | −$5.5M | $27.9M | |
| Diluted EPS | −$0.51 | −$0.22 | −$0.16 | −$0.19 | −$0.18 | $0.89 | |
| Gross margin | — | — | 100.0% | — | — | 100.0% | |
| Operating margin | — | — | -6,324.4% | — | — | 78.8% |
Fiscal years (4-quarter sums)FY24 $0 · FY25 $90.0K
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $36.5M · Total debt $1.3M · Total assets $40.2M · Shareholders' equity $30.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 31.37M · Float 31.19M · 99.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 1.26M | 4.00% | 13F | May 15, 2026 |
| Acadian Asset Management LLC | 600.8K | 1.91% | 13F | May 13, 2026 |
| Millennium Management LLC | 564.6K | 1.80% | 13F | May 15, 2026 |
| Renaissance Technologies LLC | 471.6K | 1.50% | 13F | May 14, 2026 |
| BlackRock, Inc. | 371.2K | 1.18% | 13F | May 13, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Novartis (ADR)
Prostate radioligand leader with a competing actinium-225 program.
- AstraZeneca (ADR)
Ac-225 prostate program and solid-tumor drugs overlap across three arenas.
- Telix Pharmaceuticals
PSMA radioligands contest the prostate-radiotherapy pathway.
- Pfizer
Marketed CD33 ADC is the direct therapeutic benchmark in AML.
- Bristol-Myers Squibb
Ac-225 platform and solid-tumor pipeline compete for RPT capacity.
- Johnson & Johnson
EGFR-directed therapy is a major NSCLC standard-of-care threat.
- Cellectar Biosciences
Radioconjugate platform overlaps in radiotherapy development and supply.
- Perspective Therapeutics
Lead-212 platform competes for alpha-therapy capacity and trial sites.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Actinium Pharmaceuticals | $1.02 | +0.99% | $31.7M | 2.8 | — | 0.9 | — |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Telix Pharmaceuticals | $11.29 | +0.18% | $3.82B | 113.3 | — | 4.0 | +22.8% |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Cellectar Biosciences | $2.60 | +3.39% | $20.2M | — | — | — | — |
| Perspective Therapeutics | $3.21 | +3.67% | $354.7M | — | — | 969.1 | −72.1% |
| Median | 27.7 | 15.2 | 4.1 | +5.7% |